Windlas Biotech Ltd (WINDLAS) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Windlas Biotech reported its 10th consecutive quarter of record revenue performance.
- EPS for Q1 FY26 was 8.4, a 30% YoY increase.
- A dividend of 12.2 crores (5.8 per share) was paid to shareholders for FY25.
- Revenue growth for the quarter was 19.9%, driven by contributions from all three business verticals.
- Plant 6 upgrade and injectable facilities expansion are on track.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.